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Vascular endothelial cell growth inhibitor (VEGI) is a recently identiﬁed antiangiogenic cytokine that belongs to the TNF
superfamily, and could eﬀectively inhibit endothelial cell proliferation and angiogenesis. Synthetic peptide CTT (CTTHWGFTLC)
hasbeenfoundtosuppressinvasionandmigrationofbothtumorandendothelialcellsbypotentandselectiveinhibitionofMMP-2
and MMP-9. To prepare chimeric protein VEGI-CTT for more potent antitumor therapy, the recombinant expression vector pET-
VEGI-CTT was constructed. This fusion protein was expressed in inclusion bodies in E. coli BL21 (DE3), and was refolded and
puriﬁed by immobilized metal aﬃnity chromatography using His-tag. Puriﬁed VEGI-CTT protein was characterized by prolifera-
tionassaysoftheendothelialcellsandcaseindegradationassayinvitro.TheresultsdemonstratedthatchimericproteinVEGI-CTT
had a potent activity of antiangiogenesis through inhibiting the proliferation of endothelial cells, and could eﬀectively reduce the
activity of MMP-2 and MMP-9. The preliminarily in vivo study demonstrated that chimeric protein VEGI-CTT had more potent
antitumor activity than VEGI and/or CTT peptide against CA46 human lymphoma xenografts in nude mice. Thus, these facts that
are derived from the present study suggest that the chimeric protein VEGI-CTT may be used for tumor therapy in the future.
Copyright © 2008 Jiping Cai et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
The success of applying an antiangiogenic agent Avastin [1]
in clinical settings for cancer treatment provided the ﬁrst
set of evidence to support the hypothesis that inhibition
of tumor neovascularization can bring signiﬁcant beneﬁt
to cancer therapy [2]. Because neovascularization under
either physiologic or pathologic conditions is controlled by
balance of endogenous proangiogenic and antiangiogenic
factors,animportantapproachtodeveloptherapeuticagents
for cancers and other angiogenesis-driven diseases is to use
endogenous antiangiogenic factors [3].
Vascular endothelial growth inhibitor (VEGI), also
known as tumor necrosis factor superfamily (member 15
(TNFSF15) and TL1A), is a recently identiﬁed antiangio-
genic cytokine [4–6] .T h eV E G Ig e n ei se x p r e s s e dp r e d o m i -
nantly in endothelial cells, and the VEGI mRNA is detectable
in many adult human organs, suggesting a physiologic role
for this unique gene in the maintenance of the normal vas-
culature [7]. Previous reports showed that VEGI is a potent
and speciﬁc inhibitor of endothelial cell growth [4–7]. There
arethreediﬀerentialsplicingisoforms:VEGI-251,VEGI-192,
and VEGI-174 [8–10]. The initially reported VEGI protein is
composed of 174 amino acids [4, 5]. Hydrophobic analysis
predicted VEGI-174 to be a type II transmembrane protein,
similartomosttumornecrosisfactor(TNF)familymembers
[9]. Recombinant VEGI comprising only the putative extra-
cellular domain exhibited eﬀective inhibition of endothelial
cell growth but had no eﬀect on the proliferation of breast
tumor cells or smooth muscle cells [4]. Full-length VEGI-
174 was found, however, to have no eﬀect on tumor growth
when overexpressed in cancer cells [5], whereas a secretable
fusionprotein (sVEGI) comprising a secretion signal peptide
and the putative extracellular domain of VEGI-174 inhibited
tumor growth when overexpressed in cancer cells [5]. This
indicates that a solubilized extracellular domain of VEGI is
responsible for its biological activity.
Several lines of evidence suggested that tumor growth,
angiogenesis, and metastasis are dependent on matrix met-
alloproteinase (MMP) activity. The two MMPs most closely
correlated with metastasis potential are the 72kDa MMP-
2 (gelatinase A) and the 92kDa MMP-9 (gelatinase B)
[11, 12]. The synthetic CTTHWGFTLC-deca peptide (CTT
peptide) has been recently described as speciﬁc and selective2 Journal of Biomedicine and Biotechnology
inhibitor for MMP-2 and -9, which belongs to a novel class
of cyclic tissue-permeable peptides containing an HWGF
motif, and could not inhibit other MMPs or gelatinolytic
serine proteinases [13, 14]. CTT peptide has been evidenced
to suppress invasion and migration of both tumor and
endothelial cells in vitro, prevent the growth and invasion of
tumors in mice, and speciﬁcally home to tumor vasculature
expressing gelatinases (MMP-2 and -9) in vivo.
The objective of our study was to prepare chimeric
protein VEGI (extracellular domain)-CTT for more potent
antitumor therapy. In the present study, we successfully
expressed and puriﬁed recombinant protein VEGI-CTT
in E. coli. The puriﬁed VEGI-CTT showed inhibition of
endothelial cell proliferation and formation of capillary-like
tubes by ABAE cells. In addition, the chimeric protein VEGI-
CTT potently reduced the activity of MMP-2 and MMP-9.
The preliminarily in vivo study demonstrated that chimeric
protein VEGI-CTT had more potent antitumor activity than
VEGI or CTT peptide against CA46 human lymphoma
xenografts in nude mice.
The results described here suggest that bacterial-
expressed VEGI-CTT could permit further study on its
inhibitory activity of tumor growth, invasion or metastasis,
molecular mechanism, and potential application for antian-
giogenesis therapy of tumor clinically.
2. MATERIALS AND METHODS
2.1. Materialsandcelllines
NIH 3T3 cells, lymphoma cell line CA46, and liver cancer
cell line HepG2 were purchased from the American Type
Culture Collections (ATCC, Rockville, Md, USA). Adult
bovine aortic endothelial (ABAE) cells, human umbilical
cord vein endothelial (HUVE) cells, and human vascular
smoothmuscle(HVSM)cellswerepurchasedfromClonetics
(San Diego, Calif, USA). All cells were maintained in their
recommended medium.
Chelating Sepharose Fast Flow and Superdex75 resin
were obtained from Amersham Pharmacia Biotech (USA),
and isopropyl-β-D-thiogalactopyranoside (IPTG) was pur-
chased from Sigma-Aldrich (USA). The expression vec-
tor pET30a(+), which contains a T7 promoter, His-Tag
sequence, and an ampicillin resistance gene, and bacterial
strains BL21(DE3) were purchased from Merck Biosciences
(Germany). The plasmid pSW200 which contains full-length
VEGI was a kind gift from Dr. Jingjuan Yao. The PCR
reagents and the molecular biology enzymes were purchased
from Takara Bio Inc. (Japan). BCA protein assay reagent
was from Pierce Biotechnology (Ill, USA). CTTHWGFTLC-
decapeptidewaschemicallysynthesized.RecombinantVEGI
protein was previously generated by our lab and used as
control in the present study.
2.2. Constructionofprokaryoticexpression
vectorpET-VEGI-CTT
A prokaryotic expression vector pET-VEGI-CTT was con-
structed by subcloning the fragment containing the VEGI-
CTT gene. The recombinant cDNA sequence encoding
VEGI-CTT was ampliﬁed by PCR from the original plasmid
pSW200 containing full-length VEGI cDNA using a for-
ward primer P1: 5 -TCCTCTAGAATGTGTACAACTCAC-
TGGGGTTTCACACTTTGCGTGAGACAAACTCCCACA-
3  and a reverse primer P2: 5 -CGCCTCGAGCTATAG-
TAAGAAGGCTCC-3 . The forward primer contained an
Xba I site followed by CTT (CTTHWGFTLC) sequence and
the N-terminal sequence of VEGI extracellular domain. The
reverse primer possessed a complementary sequence of the
C-terminus of VEGI extracellular domain, a stop codon, and
an Xho I site. The ﬁnal PCR product was directly cloned into
the pGEM-T vector and then subjected to DNA sequencing
to verify the desired sequence. PCR conditions consisted of
30 cycles of 94◦C for 0.5 minute, 55◦Cf o r0 . 5m i n u t e ,a n d
72◦Cfor1.5minutes.ThePCR-ampliﬁedDNAfragmentwas
separated on 1% agarose gels containing ethidium bromide,
and then subjected to DNA sequencing to verify the desired
sequence. The ampliﬁed cDNA fragment was subcloned
into E. coli expression vector pET30a(+) to construct the
prokaryotic expression vector pET-VEGI-CTT (Figure 1).
2.3. Expressionandpuriﬁcationofchimericprotein
E. coli BL21(DE3) was transformed with expression plasmid
pET-VEGI-CTT. Bacterial cultures were incubated at 37◦C
in LB growth medium with antibiotic selection (100ng/mL
ampicillin), and grown until early log phase (A600 =0.4–0.8).
The targeted protein expression was induced at 37◦Cb y
the addition of IPTG to a ﬁnal concentration of 1μM, and
incubated with shaking for 2–8 hours. The bacteria were
collected by centrifugation at 4000rpm for 30 minutes.
The pellet was resuspended in 20μM Tris-HCl (pH 8),
sonicated at maximal output, and centrifuged at 12000rpm
for 30 minutes at 4◦C. The pellet was an inclusion body
which was denatured by 8M urea for 2 hours at room
temperature, then centrifuged at 10000rpm for 30 minutes
at 4◦C, and the supernatant was ﬁltered (0.45μMp o r e s )
and loaded at room temperature onto an His-Ni2+ metal
aﬃnity column pre-equilibrated with 8M urea, 100μM
NaH2PO4,1 0 μM Tris, and 10μM imidazole. Refolding of
the bound protein is performed by the use of a linear 8–
0M urea gradient, starting with the equilibrating buﬀer
above and ﬁnishing with 50 column volumes of equilibrating
buﬀer without urea, then eluted with 5 column volumes
of eluting buﬀer (20μM phosphate, 500μM NaCl, and
300μM imidazole). Protein concentration was determined
by bicinchoninic acid (BCA) assay.
2.4. SDS-PAGEandWesternblotting
To conﬁrm and compare the quality of recombinant protein
expression, 10–12μL from each fraction were analyzed by
SDS-PAGE (12% gels) followed by staining with Coomassie
brilliant blue R-250. For western blotting analysis, proteins
were electrotransferred to PVDF (Amersham-Pharmacia
Biotech) membranes using Mini Trans-Blot cell (Bio-Rad)
following manufacturer’s instruction, blocked in 0.5% BSA
in TBS (100μM Tris, 0.9% NaCl, pH 7.5), and immunore-
acted with a 1:5000 dilution of mouse anti-His monoclonalJiping Cai et al. 3
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Figure 1:SchematicrepresentationofthecloningstepsofVEGI-CTTfragmentintotheexpressionvectorpET30a(+).(a)ThevectorPsw200
containing full-length VEGI gene was used to amplify recombinant cDNA of human VEGI-CTT for 483bp by PCR. The recombinant cDNA
of human VEGI-CTT was cloned into pGEM-T, and produced pGEM-T-VEGI-CTT. (b) pET30a(+) vector with His-tag upstream of the
multiplecloningsitethatcontainsXbaIandXhoI.(c)pET30a(+)carryingXbaI-XhoIfragmentofVEGI-CTTtoproducepET30a(+)-VEGI-
CTT. The resulting fusion gene contains internal His-tag and VEGI-CTT.
antibody (TIANGEN, Beijing, China), followed by an HRP-
labeled goat antimouse IgG (Zymed, USA). Chromogenic-
based detection was performed using DAB as a staining
substrate.
2.5. Cellproliferationassay
Cells were seeded in triplicate at 3000–5000/well in 96-
well plates in IMEM (GIBCO, Gaithersburg, Md, USA)
containing 10% fetal calf serum (FCS), and cultured at 37◦C
with5%CO2.ABAEandHUVEcellculturemediacontained
additional 1ng/mL and 6 ng/mL FGF-2, respectively. VEGI-
CTT VEGI, or CTT peptide in diﬀerent concentrations was
added to each well, and the blank control wells were only
added with equal volume of PBS. The media were changed
once on day 3. The number of viable cells was determined on
day 6 by using a Coulter (Hialeah, Fla, USA) counter.
2.6. Invitroangiogenesisassay
Quantitative assessment of capillary-like tube formation by
endothelial cells cultured on collagen gels was carried out
as described previously [4]. To prepare a three-dimensional
collagen gel, 0.5mL chilled IMEM with 10% FBS and
0.7mg/mL rat tail type I collagen (BD, Franklin Lakes,
NJ, USA) was added to each well of a 24-well plate. After
formation of the collagen gel (about 1-2mm thickness),
ABAEcellswereseededat5×104 cells/well.Thecultureswere
maintained in IMEM with 10% FCS, 1ng/mL of FGF-2, 5%
CO2,a n d3 7 ◦C for 72 hours. The media were replaced with
fresh media omitting FGF-2, and were cultured for 48 hours.
Then the media were replaced with fresh media containing
20ng/mL of FGF-2. The cultures were maintained at 37◦C
for 48 hours. The gels were then ﬁxed with cold methanol.
The abundance of the capillary-like structures formed by
ABAE cells was determined by computer-assisted image
analysis. The relative intensity of the capillary-like structures
was measured as the ratio of the total length of the tubular
structures over the total areas measured (mm/mm2).
2.7. Invitroβ-caseindegradationassay
Inhibition of MMP-9 and MMP-2 by the chimeric protein
VEGI-CTT was measured using casein degradation assay
(13). Subsequently, MMP-2 (2.5 ug) or MMP-9 (2.5 ug) was
run on a 10% SDS-PAGE containing 2mg/mL β-casein. The
gel was ﬁrst washed in Triton X-100 containing buﬀer to
remove SDS, and it was cut into slices that were immersed
into the solutions containing diﬀerent concentrations of
VEGI-CTT, VEGI, or CTT peptide. After incubation for 48
h o u r sa t3 7 ◦C, the gels were stained with Coomassie Blue
and scanned, and the digested areas were quantitated using
image analysis (Global Lab Image 3.2; Data Translation Inc.
and Acuity Imaging Inc., Marlboro, Mass, USA).
2.8. Invivostudy
Six- to eight-week-old female nude mice were obtained from
thePlannedParenthoodResearchInstitute,Shanghai,China.
All animals in this study were housed under pathogen-
free conditions and were maintained in accordance with
guidelines of the Committee on Animals of the Second
Military Medical University, Shanghai, China.4 Journal of Biomedicine and Biotechnology
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Figure 2: Construction of prokaryotic expression vector pET-
VEGI-CTT. (a) DNA fragments of VEGI-CTT were ampliﬁed
by PCR. Lane 1: 100bp markers. Lane 2: VEGI-CTT fragment
of 486bp. (b) Restriction enzyme analysis of the prokaryotic
expression vector pET-VEGI-CTT. Lane 1: 100bp markers; lane 2:
pET-VEGI-CTT digested by Xba I and Xho I.
The xenograft CA46 model was carried out as described
[15]. In brief, xenografts were allowed to be established to an
average size of 50–100mm3, after which mice were random-
ized into various conditional groups. VEGI-CTT protein,
VEGI protein, or CTT peptide was given to each mouse at
designated dose via intraperitoneal injection at a frequency
of twice a week. Each mouse was measured for tumor size
using a caliper on alternate days. Animal body weight and
any sign of morbidity were also closely monitored. The
treatmentlastedfor2weeks;atpredesignedpointsmicewere
killed, and tumor xenografts were extirpated, weighed, and
correlated with the tumor size measurement.
2.9. Statisticalanalysis
Between-group diﬀerences were determined using a Stu-
dent’s t-test, and multiple treatment groups were compared
within individual experiments by analysis of variance or the
Kruskal-Wallis test. P values less than .05 were considered to
be statistically signiﬁcant.
3. RESULTS
3.1. Constructionofprokaryoticexpression
vectorpET-VEGI-CTT
The vector pSW200 containing full-length VEGI gene was
used to amplify recombinant cDNA of human VEGI-CTT by
PCR. Analysis of 1% agarose gels revealed that the resulting
fragment was ≈490bp (Figure 2(a)), and then VEGI-CTT
cDNA was cloned into pGEM-T vector for sequencing,
which showed a fragment with 486bp in length.
The ampliﬁed cDNA fragment was subcloned into
pET30a(+) to produce a prokaryotic expression vector
pET-VEGI-CTT; subsequently the resulting pET-VEGI-CTT
was identiﬁed by digestion of restriction enzymes XbaI and
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Figure 3: Expression analysis of recombinant VEGI-CTT in
BL21(DE3). (a) Time course analysis of recombinant VEGI-CTT
induction in BL21(DE3) induced by 1μM IPTG. Protein samples
werepreparedfromtheinclusion-bodyfractionofinducedbacterial
cells at time points of 2 hours (lane 3), 4 hours (lane 4), 6 hours
(lane 5), and 8 hours (lane 6) of the induction, and were resolved
on 12% SDS-PAGE. Lane 1: low molecular weight protein markers;
lane 2: uninduced control. No diﬀerence was found from lane 3
to lane 6 at 2–8 hours. (b) SDS-PAGE analysis of expression and
location of the fusion protein VEGI-CTT in the cellular fractions
of E. coli. Lane 1: eluted fraction under renaturing conditions with
500μM imidazole; lane 2: low molecular weight protein markers;
lane 3: the inclusion-body fraction; lane 4: supernatant of cell
lysates.
XhoI, which revealed that the cDNA of VEGI-CTT was
correctly inserted into the vector pET30a(+) (Figure 2(b)).
3.2. Expression,refolding,andpuriﬁcationof
chimericproteinVEGI-CTT
The resulting plasmids pET30a(+)-VEGI-CTT and the con-
trols were transformed into the E. coli BL21(DE3). This
construction of pET30a(+)-VEGI-CTT should produce a
recombinant protein of approximately 22kDa. Induction of
the strong T7 promoter controlling the expression of VEGI-
CTT in BL21(DE3) with 1μM IPTG produced recombinant
VEGI-CTT after 2 hours. It seemed that there was no
diﬀerence in expression levels from 2 to 6 hours at 37◦C
(Figure 3(a)). The recombinant protein is the major band
present at all time points of induction.
TodeterminethelocationoftherecombinantVEGI-CTT
in the cellular fractions of E. coli, the cytosolic, inclusion-
body, periplasmic, and media fractions were tested. The
recombinant protein was found only in the inclusion-body
fraction; almost no VEGI-CTT protein was observed in the
soluble fraction (Figure 3(b)). Likewise, no indication of
secreted or transferred protein was observed in the media
or periplasmic fractions. No eﬀect on the solubility of the
recombinant protein was observed by decreasing the incuba-
tion temperature or by slowing the expression by decreasing
the concentration of the IPTG (results are not shown).
Following the successful overproduction of recombinant
VEGI-CTT in the inclusion-body fraction of E. coli,w e
attempted to use the presence of the internal His-tag in the
fusion protein for renaturation and puriﬁcation on immo-
bilized metal ion-aﬃnity chromatography (Ni2+-chelating)
column. The recombinant VEGI-CTT in inclusion body wasJiping Cai et al. 5
Table 1: Puriﬁcation of chimeric protein VEGI-CTT from inclu-
sion bodies (from 1L of E. coli culture and 4.6g wet weight cells).
Steps
Total
protein
(mg)
Step
yield
(%)
Overall
yield
(%)
Cell lysate 304 — —
Inclusion body 155 100 100
Solubilization
(denaturation buﬀer
containing 8M urea)
96.3 62.1 62.1
Refolding and aﬃnity
puriﬁcation 25.5 26.6 16.5
denatured by 8M urea. A step-down urea concentration
strategy (a linear gradient from 8 to 0M urea) was applied
to the VEGI-CTT on-column refolding process. The VEGI-
CTT fusion proteins were eluted with 300μM imidazole,
with purity being greater than 90%, and they were of the
expected 22kDa (Figure 3(b)). By this strategy, a stable ﬁnal
amount of the obtained puriﬁed recombinant VEGI-CTT
was approximately 25.5mg/L of initial bacterial broth. The
refolding and puriﬁcation yield of recombinant VEGI-CTT
was about 16.5% (Table 1).
To insure that the recombinant protein we had expressed
and renatured was the protein we designed, the VEGI-
CTT was subjected to western blotting analysis using His-
tag monoclonal antibody. As shown in Figure 4, the puri-
ﬁed recombinant protein is His-immunoreactive and, as
expected, it has a molecular weight of approximately 22kDa.
3.3. ChimericproteinVEGI-CTTinhibitsthe
proliferationoftheendothelialcellsinvitro
The bioactivity of VEGI-CTT was determined by the pro-
liferation of ABAE and HUVE cells in vitro. As shown in
Figure 5(a), the protein was found to preferentially inhibit
the FGF-2-induced proliferation of ABAE and HUVE cells
in a dose-dependent manner, whereas it could not inhibit
the growth of HVSM, liver cancer HepG2 or NIH 3T3
cells. The half-maximum inhibitory concentrations (IC50)
of VEGI-CTT for ABAE and HUVE cells were about
25ng/mL and 100ng/mL, respectively. The inhibition eﬀect
of VEGI-CTT on endothelial cells was similar to that of
VEGI alone or of VEGI and CTT combined treatment at a
concentration of 40ng/mL. No eﬀect on the proliferation of
theendothelialcellsorcancercellswasobservedinthegroup
of CTT treatment (Figure 5(b)). These results suggest that
recombinant protein VEGI-CTT, which is bioactive, could
speciﬁcally inhibit proliferation of endothelial cells when
compared with other tested cell types.
3.4. Inhibitionofinvitroangiogenesisby
chimericproteinVEGI-CTT
The antiangiogenic activity of the recombinant VEGI-CTT
was examined with an in vitro angiogenesis model. In this
model, when recombinant VEGI-CTT was added to the cell
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Figure 4: Western blotting analysis of the renatured, puriﬁed
recombinant protein VEGI-CTT. Ten micrograms of VEGI-CTT
were applied into 12% SDS-PAGE, and then electrotransferred
to a PVDF membrane. Western blotting analysis was performed
using mouse anti-His-Tag monoclonal antibody (Lane 2). The
membrane was incubated with the second antibody: HRP-labeled
goat antimouse IgG. Lane 1: prestained molecular weight protein
markers. Lane 2: fusion protein VEGI-CTT of 22kDa.
cultures together with FGF-2, inhibition of the formation of
capillary-like tubes by ABAE cells was observed (Figure 6).
The relative intensities of the tubules were determined by
using computer-assisted image analysis. The IC50 value for
the inhibition was found to be approximately 40ng/mL.
VEGI used alone or VEGI and CTT combined treatment
also could inhibit the formation of capillary-like tubes by
ABAE cells similar to those of VEGI-CTT, whereas the
antiangiogenic activity of CTT was not observed (Figure 6).
Theseresultsfurtherdemonstratedthatrecombinantprotein
VEGI-CTT had a potent activity of antiangiogenesis through
inhibiting the proliferation of endothelial cells.
3.5. VEGI-CTTpotentlyreducedtheactivityof
MMP-2andMMP-9
CTT is a recently described cyclic peptide collagenase
inhibitor of MMP-2 and MMP-9. To determine whether the
recombinant protein we had expressed and renatured also
could eﬃciently inhibit the activity of MMP-2 and MMP-
9, metalloproteinase inhibitory activity of VEGI-CTT was
assessed by casein degradation assay. In order to precisely
comparethebioactivitybetweenrecombinantproteinVEGI-
CTT and CTT peptide, molar concentration was used here.
As shown in Figure 7, degradation of β-casein by MMP-
9 or MMP-2 was inhibited by VEGI-CTT, similar to that
of CTT or both CTT and VEGI. Moreover, the inhibitory
eﬀect of VEGI-CTT occurred in a dose-dependent manner.
For MMP-2, the fusion protein VEGI-CTT inhibited MMP-6 Journal of Biomedicine and Biotechnology
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Figure 5: Speciﬁc inhibition of endothelial cell proliferation by chimeric protein VEGI-CTT. Cells were seeded in triplicate at 3000–5000
cells/well in 96-well plates. Culture conditions are described in Section 2. The media were changed once on day 3. The number of viable cells
was determined on day 6 by using a Coulter counter. Mean values are presented as a function of VEGI-CTT or other agents’ concentrations.
∗P<. 05 versus that of PBS group.
2w i t ha nI C 50 of 150ng/mL (equal to 7.5μM). Caseinolysis
by MMP-9 was similarly inhibited by the protein at high
concentrations with an IC50 of 650ng/mL (equal to 30μM).
The diﬀerences of IC50 for MMP-2 and MMP-9 may be due
to the diﬀerent avidity of VEGI-CTT with them. However,
VEGI alone could not inhibit the degradation of β-casein
by MMP-9 or MMP-2. The data indicated that recombinant
proteinVEGI-CTThadsimilaractivitytotheCTTpeptideas
previouslyreported,andcouldpotentlyreducetheactivityof
MMP-2 and MMP-9 in a dose-dependent manner.
3.6. Xenograftantitumoractivity
We extended our analysis of the antitumor activity of
chimeric protein VEGI-CTT using mouse xenograft models.
Cultured CA46 lymphoma cells were implanted subcuta-
neously into nude mice, the agent treatment started upon
tumor xenograft development, and the tumor growth was
monitored for 2 weeks. Subcutaneous inoculation of 1 ×
107 CA46 cells resulted in aggressively growing tumors
in PBS treatment group (Figure 8). Tumor-bearing mice
were treated with predetermined doses of chimeric protein
VEGI-CTT, and signiﬁcant reduction in tumor burden was
observed. Treatment with 50ug/mouse VEGI-CTT twice
a week reduced tumor growth by 82.2% compared with
animalsinthePBS-treatedgroup.Incontrast,treatmentwith
50ug/mouse VEGI or CTT peptide alone merely resulted
in 49.2% and 35.1% reduction, respectively. In addition,
compared with VEGI-CTT treatment, combined treatment
with 50ug/mouse VEGI and CTT peptide had a rela-
tively low antitumor activity but also signiﬁcantly reduced
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Figure 6: Inhibition of formation of capillary-like tubules by
adult bovine aortic endothelial (ABAE) cells in collagen gels.
The experiments were carried out in triplicate. At least 9 image
areas were analyzed for each VEGI concentration. Mean values
and standard deviations are presented as a function of VEGI
concentration. ∗P<. 05 versus that of PBS group.
tumor growth by 62.9%. These results establish chimeric
protein VEGI-CTT as an eﬀective inhibitor of lymphoma
t u m o rg r o w t hi nv i v o ,a n dt h u si th a dam o r ep o t e n t
antitumor activity than VEGI, CTT, or the combination of
both.Jiping Cai et al. 7
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Figure 7: Inhibition of caseinolytic activity by the chimeric protein VEGI-CTT. MMP-2 and MMP-9 enzymes were incubated with 2mg/mL
β-casein in the absence or presence of VEGI-CTT. Proteins were separated on a 10% SDS-polyacrylamide gel, and detected with Serve blue
R. For details, see Section 2. Inhibition of MMP-2 and MMP-9 mediated β-casein degradation by VEGI-CTT at diﬀerent concentrations
with apparent IC50 of 7.5μMa n d3 0μM, respectively.
4. DISCUSSION
Angiogenesis is required for tumor growth and metastasis,
and its inhibition may be a new valuable approach to
cancer therapy. It has been demonstrated that a variety
of endogenous angiogenesis inhibitors such as angiostatin
[16], endostatin [17], restin [18, 19], canstatin [20, 21],
and tumstatin [22, 23] can lead to the suppression of
primaryandmetastatictumors’growthwithoutaﬀectingthe
normal vasculature growth. Advantages of antiangiogenic
therapy include easy access of drugs to the endothelial cell
compartment and low drug resistance. Vascular endothelial
cellgrowthinhibitor(VEGI),anovelcytokinewhichbelongs
to the TNF superfamily, is one of the most potent inhibitors
of endothelial cell proliferation and migration as well as
tumor growth in mice [4–6]. The synthetic CTTHWGFTLC-
deca peptide (CTT peptide) has been recently described as
a speciﬁc and selective inhibitor for MMP-2 and -9. CTT
peptide has been shown to suppress invasion and migration
of both tumor and endothelial cells in vitro, prevent the
growth and invasion of tumors in mice, and speciﬁcally
home to tumor vasculature expressing gelatinases (MMP-2
and -9) in vivo [13, 14].
In the present study, we incorporated the extracellular
domainofVEGIwithCTTHWGFTLC-decapeptideforanti-
tumor therapy by more potent antiangiogenesis. The fusion
protein VEGI-CTT was expressed in E. coli. Recombinant
proteins expressed in bacteria often form inclusion bodies,
especially when they are expressed at high levels [24]. In
our case, the expressed protein formed inclusion bodies.
Therefore, an eﬃcient and convenient refolding system
that would help the puriﬁcation of VEGI-CTT is needed
[25]. Renaturation of VEGI-CTT is very crucial because
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Figure 8: Eﬀect of chimeric protein VEGI-CTT in treating CA46
human lymphoma xenograft-bearing nude mice. Nude mice were
inoculated with CA46 human lymphoma cells, and the treatment
started upon tumor xenograft establishment in nude mice. Tumor
xenograft-bearing nude mice were injected with indicated doses of
VEGI-CTT, VEGI, CTT, or VEGI and CTT combined treatment
for two weeks, and tumor volumes were measured on alternate
days. Mean values and standard deviations are presented as tumor
volumesineachgroup(n = 9).Theexperimentswererepeatedwith
similar results.
it is closely related with the ﬁnal yields. There are many
methods for refolding, such as dilution, dialysis, and gel
ﬁltration [26–28]. In this work, we chose on-column metal8 Journal of Biomedicine and Biotechnology
ion-aﬃnity chromatography for protein refolding. The
purity of inclusion bodies is a key factor. Previous reports
demonstratethatthewashingstepcanremovecontaminants,
especially proteins that may have been absorbed onto the
hydrophobic inclusion bodies during processing and could
aﬀect protein-refolding yield [29]. In the present study,
inclusion bodies were washed three times. Washing with 2M
urea using 1% Triton X-100 eﬀectively removed remaining
cellular proteins. The ﬁnal purity of the inclusion bodies
could reach 80% after the last washing, facilitating the
following puriﬁcation and refolding. Another important
factor to inﬂuence the yield of refolding is the time and
ﬂow rate. We tested three diﬀerent times (1, 2, and 4 hours)
and three diﬀerent ﬂow rates (2, 1, and 0.5mL/min) for on-
column refolding. The result showed that there was a lot of
precipitation at 2mL/min (1, 2, and 4 hours), with some at
1mL/min(1and2hours)and0.5mL/min(1hour)andlittle
at 0.5mL/min (4 hours). We chose 0.5mL/min (4 hours)
as the ﬁnal ﬂow rate for refolding process. This provided
the opportunity to generate more soluble refolded VEGI-
CTT and increase the yield of the protein. In our study,
we use Ni2+-chelating column to refold, purify, and reform
disulﬁde bonds of VEGI-CTT in one step. By this strategy,
an amount of the obtained refolded recombinant VEGI-
CTT was approximately 25.5mg/L of initial bacterial broth.
The results indicate that this process for renaturation and
puriﬁcation of VEGI-CTT is suitable and eﬀective.
Our purpose was to express and purify VEGI-CTT, and
useactiveVEGI-CTT toobtainmorepotent antitumoreﬀect
than that of VEGI or CTT peptide alone. So we conﬁrmed
the bioactivities of VEGI-CTT by a series of assays in
vitro. The results showed that VEGI-CTT has both activities
exerted by VEGI or CTT alone. VEGI-CTT could eﬀectively
inhibit endothelial cell proliferation and the formation of
capillary-like tubes by ABAE cells; meanwhile, VEGI-CTT
could potently reduce the activity of MMP-2 and MMP-
9. Importantly, the further in vivo study demonstrated that
chimeric protein VEGI-CTT has more potent antitumor
activity not only than that of VEGI or CTT, but also than
that of the addition of VEGI and CTT in combination.
The explanation may be that chimeric protein VEGI-CTT
can more eﬃciently increase the half-life of CTT than CTT
peptide used alone in vivo. Further studies with recombinant
VEGI-CTT are underway to test the ability to inhibit tumor
invasion or metastasis in vivo, which may give insight into
its unique molecular mechanisms underlying the antitumor
actions of VEGI-CTT.
ABBREVIATIONS
VEGI: Vascular endothelial cell growth inhibitor
MMP: Matrix metalloproteinase
MMP-2: 72-kDa gelatinase/type IV collagenase
MMP-9: 92-kDa gelatinase/type IV collagenase.
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